Radicava (edaravone), an approved treatment for amyotrophic lateral sclerosis (ALS), can be taken for up to one year without losing its effectiveness, and benefits patients who delay its start — say, after six months of placebo in a clinical trial, a post hoc analysis of that Phase 3…
News
Tikomed has secured $5.5 million in financing from investors to support the ongoing clinical development of ILB, its lead therapy candidate for degenerative neurological diseases, including amyotrophic lateral sclerosis (ALS). The funding also will help develop Ibsolvmir, a therapy to increase the effectiveness of transplanting cells to treat patients…
Target ALS and The ALS Association will jointly fund two projects focused on the development of new tests to evaluate TDP-43’s potential as a biomarker of amyotrophic lateral sclerosis (ALS). Nearly all ALS cases are characterized by the formation of toxic aggregates (clumps) containing the TDP-43 protein. These…
News
‘Hero’ Proteins Protect Cells from Toxic Clumps Underlying ALS, Other Neurodegenerative Diseases
Human cells produce a type of proteins, termed “Heroes,” that protect against the formation of toxic protein aggregates involved in several neurological conditions, including amyotrophic lateral sclerosis (ALS), and are extremely resistant to harsh conditions, early study results show. Organisms naturally use Hero proteins as molecular shields to stabilize…
Levels of specific proteins found in specialized immune cells — white blood cells like lymphocytes and monocytes — can serve as biomarkers for amyotrophic lateral sclerosis (ALS), helping doctors to diagnose the disease and its likely progression, a study reported. These specialized immune cells, called peripheral blood…
Bloom Science, a biopharmaceutical company, announced it has received a $500,000 grant from The ALS Association to advance a treatment that, by managing bacteria populations in the gut, might restore neurotransmitters in the brain to ease motor symptoms of…
Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
A molecule that prevents cell death was able to prevent and reverse clumping of a mutant form of the protein superoxide dismutase 1 (SOD1) — the underlying cause of some familial amyotrophic lateral sclerosis (ALS) cases. …
Muscle cell activity helps to promote motor nerve cell repair after injury, scientists found in using a device to model motor neuron and muscle cell interaction. They believe this finding could be relevant to diseases like amyotrophic lateral sclerosis (ALS) that imperil motor neuron survival. The device was described…
Amyotrophic lateral sclerosis (ALS) patients with mild to moderate disease progression show an ability to drive that’s comparable to other adults, despite weaknesses with movement and cognition, a small study using a driving simulator suggests. The study included only patients who were still driving, and its researchers caution that…
Recent Posts
- MDA Engage: ALS neurologist sees real reasons for renewed optimism
- Tongue exercise may help nerve cells compensate for damage linked to ALS
- Reaching back in time to remember our ‘normal’ life before ALS
- Protein may drive toxic clump buildup in SOD1-linked ALS, study finds
- 1 sign of ALS may be detected up to 15 years before diagnosis